Journey Medical Résultats passés
Passé contrôle des critères 2/6
Journey Medical's earnings have been declining at an average annual rate of -11.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 9.5% per year. Journey Medical's return on equity is 7.5%, and it has net margins of 1.1%.
Informations clés
-11.4%
Taux de croissance des bénéfices
-4.5%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 6.0% |
| Taux de croissance des recettes | 9.5% |
| Rendement des fonds propres | 7.5% |
| Marge nette | 1.1% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Oct 03
Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Sep 14Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
May 06Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
May 12Ventilation des recettes et des dépenses
Comment Journey Medical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 78 | 1 | 37 | 13 |
| 31 Mar 24 | 80 | -4 | 39 | 13 |
| 31 Dec 23 | 79 | -4 | 44 | 8 |
| 30 Sep 23 | 80 | -12 | 48 | 10 |
| 30 Jun 23 | 61 | -39 | 55 | 11 |
| 31 Mar 23 | 63 | -38 | 58 | 12 |
| 31 Dec 22 | 74 | -30 | 59 | 11 |
| 30 Sep 22 | 75 | -41 | 61 | 9 |
| 30 Jun 22 | 79 | -41 | 56 | 7 |
| 31 Mar 22 | 76 | -46 | 48 | 18 |
| 31 Dec 21 | 63 | -44 | 40 | 17 |
| 30 Sep 21 | 59 | -20 | 31 | 15 |
| 30 Jun 21 | 49 | -9 | 26 | 14 |
| 31 Mar 21 | 45 | 4 | 23 | 0 |
| 31 Dec 20 | 45 | 5 | 22 | 0 |
| 31 Dec 19 | 35 | 4 | 19 | 0 |
Des revenus de qualité: DERM has a high level of non-cash earnings.
Augmentation de la marge bénéficiaire: DERM became profitable in the past.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: DERM has become profitable over the past 5 years, growing earnings by -11.4% per year.
Accélération de la croissance: DERM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Bénéfices par rapport au secteur d'activité: DERM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement des fonds propres
ROE élevé: DERM's Return on Equity (7.5%) is considered low.